细胞角质蛋白19与肝癌临床病理关系的探讨  

Study on the relationship between serum cytokeratin 19 level in hepatocellular carcinoma patients and the clinicu-pathologic characteristics

作　　者：李雁[1] 汤钊猷[2] 田波[2] 钦伦秀[2] 叶胜龙[2] 孙瑞霞[2] 

机构地区：[1]武汉大学中南医院肿瘤科武汉大学医学院肿瘤研究所,430071 [2]上海复旦大学肝癌研究所中山医院

出　　处：《中华肝脏病杂志》2004年第6期341-343,共3页Chinese Journal of Hepatology

基　　金：国家重点基础研究发展规划(973项目):恶性肿瘤发生与发展的基础性研究(G1998051210);武汉大学211工程重点学科基金

摘　　要：目的 分析原发性肝细胞癌(HCC)患者血清中细胞角质蛋白(CK)19水平与临床病理指标的关系。方法 用放射性核素标记的免疫吸附试验(ELISA)检测101例正常人血清中CK19浓度,确定参考范围;然后测定108例HCC患者术前血清CK19浓度,分析CK19升高者的临床病理特征。结果 正常人血清CK19浓度单侧98％可信区间上限是2.3μg/L。108例HCC患者中,24例(22.2％)CK19水平升高,浓度范围是2.4～4 5.5μg/L,其中12例(11.1％)只有CK19升高而AFP正常。低分化癌的比例在CK19升高者中(37.5％,9/24)高于CK19正常者(20.2％,17/84,x^2=7.362,P<0.05)。门静脉癌栓的比例在CK19升高组(25.0％,6/24)高于CK19正常组(6.0％,5/84,x^2=7.403,P<0.01);TNM Ⅲ/Ⅳ期肿瘤的比例在CK19升高组(54,2％,13/24)亦高于CK19正常组(21.4％,18/84,x^2=13.300,P<0.005)。结论 部分HCC患者血清中CK19升高,可能与肿瘤门静脉癌栓、分化程度更低、病期更晚有关。Objective As our previous comparative proteomics study on high and low metastasis human hepatocellular carcinoma (HCC) cell strains revealed that cytokeratin 19 (CK19) was related to higher metastasis potential, we further investigated the relationship between serum CK19 level in HCC patients and their clinico-pathologic characteristics. Methods Serum CK19 levels of 101 normal controls and 108 pathology-proven HCC patients were determined using radioimmunoassay, and the their correlation with clinico-pathologic parameters were studied. Results The upper limit of one-side 98% confidence interval of normal serum CK19 level was 2.3μg/L. Among 108 HCC patients, 24 (22.2%) had increased serum CK19 level, ranging from 2.4～45.5μg/L. There were 12 patients (11.1%) with increased CK19 level but normal AFP level. The percentage of poor differentiated tumor was higher in CK19 increased cases (37.5%, 9/24) than in CK19 normal cases (20.2%, 17/84) (x^2=7.362, P<0.05). Moreover, the presence of portal vein tumor emboli was significantly higher in CK19 increased cases (25.0%, 6/24) than in CK19 normal cases (6.0%, 5/84) (x^2=7.403, P<0.01). In addition, the percentage of TNM stage Ⅲ/Ⅳ tumor was significantly higher in CK19 increased patients (54.2%, 13/24) than in CK19 normal cases (21.4%, 18/84) (x^2=13.300, P<0.005). Conclu- sions Some HCC patients do have increased serum CK19 level, which could be related to portal vein tumor emboli, poor tumor differentiation and advanced tumor stages.

关 键 词：细胞角质蛋白19 血清 原发性肝细胞癌 检测 临床病理 

分 类 号：R735.7[医药卫生—肿瘤]